Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Moderna

Pfizer

Bristol Myers Squibb is trading at a significant discount. Moderna has a lot of irons in the fire.

3 Surprisingly Underrated Stocks to Buy Right Now

Bristol-Myers Squibb's stock is poised to rise due to the FDA approval of Cobenfy, a novel antipsychotic for schizophrenia, and improved technicals. The company's $14 billion acquisition of Karuna Therapeutics and subsequent drug approval validates the investment and supports a higher stock price. BMY's strong oncology portfolio, including Opdivo and Revlimid, and recent acquisitions bolster its fundamentals, targeting a price range of $59.50 to $61.60.

Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval

On Thursday, the FDA approved Bristol Myers Squibb & Co's BMY Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

Bristol-Myers Squibb's acquisition of Karuna for $14bn and the subsequent FDA approval of Cobenfy, a novel schizophrenia drug, represents a significant strategic win. Cobenfy, the first new schizophrenia treatment in 35 years, has peak sales potential estimated at $7.5bn, validating Bristol-Myers' investment and boosting its market position. Despite recent financial struggles and high debt, Bristol-Myers' robust pipeline and strategic acquisitions position it for substantial revenue growth by 2030.

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma name's schizophrenia treatment, Cobenfy.

Pharma Stock Rises on Cleared Schizophrenia Treatment

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #PSORIATYK--BMS Presents New Data from Two Trials Demonstrating Sotyktu Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting.

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting

The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.

Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment

Shares of Bristol Myers Squibb (BMY) rose Friday, a day after the Food and Drug Administration (FDA) approved the use of what the pharmaceutical firm called the first treatment for schizophrenia in decades.

Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval

Bristol Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) shares moved higher after the pharmaceutical company's schizophrenia drug was approved by the Food and Drug Administration (FDA), marking the first new treatment to be approved for the mental illness in decades.   The company said its twice-daily pill, sold under the brand name COBENFY, will be available starting in October.

Bristol Myers Squibb shares move higher on FDA approval of schizophrenia drug

On Thursday, the FDA approved Bristol Myers Squibb & Co's BMY Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.

Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades

Bristol-Myers Squibb is rated a "Buy" for long-term investors due to the revenue potential of KarXT (Cobenfy) and advancements in its oncology portfolio. Despite recent financial setbacks, BMY's strategic acquisitions and strong drug portfolio growth are poised to drive significant revenue from 2025 onwards. The Company offers a compelling dividend yield of nearly 5%, with a strong dividend growth rate, making it attractive for value investors.

Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress

The drug is one of an emerging class of drugs that has drawn the interest of large pharma companies.

Bristol Myers Stock Jumps. Why Approval for Its Schizophrenia Drug Is Ground Breaking.

Bristol Myers Squibb stock (NYSE: BMY) will be in focus in the near term after the U.S. FDA approved Cobenfy for the treatment of Schizophrenia. This is a big approval for the company, given that Cobenfy doesn't have the classic side effects seen in other antipsychotic drugs.

Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia drug.

Bristol-Myers Squibb stock jumps on schizophrenia drug approval

The US Food and Drug Administration (FDA) has approved Cobenfy, the first new drug for schizophrenia in over 30 years, developed by Bristol Myers Squibb. Taken as a twice-daily pill, the treatment combines xanomeline and trospium chloride to manage common symptoms such as hallucinations and delusions.

US drug regulator approves the first new schizophrenia drug in 30 years

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #COBENFY--U.S. FDA Approves Bristol Myers Squibb's COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults.

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock rose late, signaling a breakout Friday.

Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout

The U.S. health regulator approved Bristol Myers Squibb's schizophrenia drug on Thursday, providing patients with a treatment option that reduces symptoms of the mental disorder without common side effects, the company said.

US FDA approves Bristol Myers' schizophrenia drug

The Food and Drug Administration approved Bristol Myers Squibb's highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades.  The company expects the twice-daily pill, which will be sold under the brand name Cobenfy, to be available in late October.

FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades

2Seventy Bio

2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.

TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study

AbbVie

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – AbbVie stock . BMY stock trades at a much lower multiple of 2.2x revenues, versus 6.2x for ABBV.

Bristol Myers Squibb Vs. AbbVie Stock

2seventy bio, Inc TSVT and its partner Bristol Myers Squibb & Co BMY, will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone for newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability

Amgen

Alexandria Real Estate Equities

Blackrock Inc

Boston Properties

Cisco Systems

Douglas Emmett

Home Depot

iShares Core High Dividend ETF

Highwoods Properties

Coca-Cola

Lockheed Martin

Medical Properties Trust

PepsiCo

Rexford Industrial Realty

Schwab US Dividend Equity ETF

iShares 0-3 Month Treasury Bond ETF

SL Green Realty

SPDR S&P 500 ETF Trust

Texas Instruments

Vornado Realty Trust

Verizon

As a dividend growth investor focused on income, I recommend raising cash and selling lower-quality stocks due to potential recession risks. Historical data shows that rate cuts often precede recessions, making it prudent to increase cash positions and reduce exposure to vulnerable stocks. Despite some reasonable buying opportunities, I prefer holding cash in ETFs like SGOV for liquidity and safety during uncertain economic times.

Raise Cash And Sell Trash

Baxter

CVS Health

Humana

Healthcare is undervalued despite being the top sector for earnings growth, making it an attractive investment with solid fundamentals and the potential for explosive returns in 2025. Investing in healthcare ETFs or individual undervalued healthcare stocks can capitalize on the sector's recovery and expected double-digit growth through 2026. Screening for blue-chip healthcare stocks with solid fundamentals and fair valuations can yield superior returns, including these five coiled spring blue chips.

5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #DAYBREAK--New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis.

News for Bristol-Myers Stock (BMY)